ダウンロード数: 94
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
s41598-018-28405-x.pdf | 923.36 kB | Adobe PDF | 見る/開く |
タイトル: | Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study |
著者: | Shirakashi, Mirei https://orcid.org/0000-0003-1135-0463 (unconfirmed) Yoshifuji, Hajime https://orcid.org/0000-0001-7082-4900 (unconfirmed) Kodama, Yuzo Chiba, Tsutomu Yamamoto, Motohisa Takahashi, Hiroki Uchida, Kazushige Okazaki, Kazuichi Ito, Tetsuya Kawa, Shigeyuki Yamada, Kazunori Kawano, Mitsuhiro Hirata, Shintaro Tanaka, Yoshiya Moriyama, Masafumi Nakamura, Seiji Kamisawa, Terumi Matsui, Shoko Tsuboi, Hiroto Sumida, Takayuki Shibata, Motoko Goto, Hiroshi Sato, Yasuharu Yoshino, Tadashi Mimori, Tsuneyo |
著者名の別形: | 白柏, 魅怜 吉藤, 元 児玉, 裕三 千葉, 勉 山本, 元久 高橋, 裕樹 内田, 一茂 岡崎, 和一 伊藤, 哲也 川, 茂幸 山田, 和徳 川野, 充弘 平田, 信太郎 田中, 良哉 森山, 雅文 中村, 誠司 神澤, 輝実 松井, 祥子 坪井, 洋人 住田, 孝之 柴田, 元子 後藤, 浩 佐藤, 康晴 吉野, 正 三森, 経世 |
キーワード: | Connective tissue diseases Predictive markers |
発行日: | 6-Jul-2018 |
出版者: | Springer Nature |
誌名: | Scientific Reports |
巻: | 8 |
論文番号: | 10262 |
抄録: | Glucocorticoids (GC) are effective for treating IgG4-related disease (IgG4-RD); however, relapse is often observed. We conducted a retrospective multicentre study to investigate risk factors in GC regimens associated with relapses of IgG4-RD. Data on 166 patients with definitive IgG4-RD diagnosis were collected from 12 institutions. Comprehensive surveillance of clinical backgrounds and GC regimens as well as multivariate analysis of factors associated with treatment responses and relapses was performed. To determine the initial maximal GC dose, the patients were stratified into three groups depending on the initial prednisolone (PSL) dosage: <0.39, 0.4–0.69 and >0.7 mg/kg/day. The multivariate analysis extracted the disease duration and reduction speed of initial GC dose. Patients treated with initial GC <0.39 or >0.7 mg/kg/day of PSL showed higher relapse rates than those treated with 0.4–0.69 mg/kg/day. The relapse rates were significantly higher in patients with fast reduction of the initial dose (>0.4 mg/day) than in patients with slow reduction (<0.4 mg/day). To avoid relapse, 0.4–0.69 mg/kg/day of initial PSL with slow reduction speed (<0.4 mg/day) is needed in the early treatment of IgG4-RD. |
著作権等: | © The Author(s) 2018. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
URI: | http://hdl.handle.net/2433/250002 |
DOI(出版社版): | 10.1038/s41598-018-28405-x |
PubMed ID: | 29980706 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。